GeoVax to Present at the Emerging Growth Conference on August 21, 2024
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines, will present at the Emerging Growth Conference on August 21, 2024. Chairman and CEO David Dodd will deliver a live, interactive presentation at 4:10pm ET, discussing recent Mpox developments and milestones related to the BARDA Project NextGen Award for their next-generation COVID-19 vaccine.
The event offers shareholders and investors the opportunity to interact with Mr. Dodd in real-time. Attendees can submit questions in advance or during the event. Registration is required to attend and receive updates. For those unable to join live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
GeoVax Labs, Inc. (Nasdaq: GOVX), un'azienda biotecnologica che sviluppa immunoterapie e vaccini, presenterà alla Emerging Growth Conference il 21 agosto 2024. Il presidente e CEO David Dodd terrà una presentazione interattiva in diretta alle 16:10 ET, discutendo degli sviluppi recenti legati a Mpox e delle tappe importanti relative al BARDA Project NextGen Award per il loro vaccino di prossima generazione contro il COVID-19.
L'evento offre agli azionisti e agli investitori l'opportunità di interagire con il signor Dodd in tempo reale. I partecipanti possono inviare domande in anticipo o durante l'evento. È necessaria la registrazione per partecipare e ricevere aggiornamenti. Per coloro che non possono unirsi in diretta, sarà disponibile una registrazione dell'evento su EmergingGrowth.com e sul canale YouTube di Emerging Growth.
GeoVax Labs, Inc. (Nasdaq: GOVX), una empresa biotecnológica que desarrolla inmunoterapias y vacunas, se presentará en la Emerging Growth Conference el 21 de agosto de 2024. El presidente y CEO David Dodd realizará una presentación interactiva en vivo a las 4:10 p. m. ET, donde discutirá los recientes desarrollos de Mpox y los hitos relacionados con el BARDA Project NextGen Award para su vacuna de próxima generación contra el COVID-19.
El evento ofrece a los accionistas e inversores la oportunidad de interactuar con el Sr. Dodd en tiempo real. Los asistentes pueden enviar preguntas con antelación o durante el evento. Se requiere registrarse para asistir y recibir actualizaciones. Para aquellos que no puedan unirse en vivo, habrá una grabación archivada disponible en EmergingGrowth.com y en el canal de YouTube de Emerging Growth.
GeoVax Labs, Inc. (Nasdaq: GOVX)는 면역 치료제 및 백신을 개발하는 생명공학 회사로, 2024년 8월 21일에 Emerging Growth Conference에서 발표할 예정입니다. 회장 겸 CEO인 David Dodd는 오후 4시 10분(ET)에 라이브 인터랙티브 발표를 진행하며, 최신 Mpox 개발 및 차세대 COVID-19 백신을 위한 BARDA Project NextGen Award와 관련된 주요 이정표에 대해 논의할 것입니다.
이번 이벤트는 주주와 투자자에게 Dodd 씨와 실시간으로 소통할 수 있는 기회를 제공합니다. 참석자는 사전 또는 이벤트 중에 질문을 제출할 수 있습니다. 참석을 원하시는 분은 등록이 필요하며 업데이트를 받을 수 있습니다. 라이브로 참여할 수 없는 분들을 위해, EmergingGrowth.com 및 Emerging Growth YouTube 채널에서 아카이브된 웹캐스트가 제공될 예정입니다.
GeoVax Labs, Inc. (Nasdaq: GOVX), une entreprise de biotechnologie développant des immunothérapies et des vaccins, fera une présentation lors de la Emerging Growth Conference le 21 août 2024. Le président et PDG David Dodd animera une présentation interactive en direct à 16h10 ET, discutant des récentes évolutions de Mpox et des jalons liés au BARDA Project NextGen Award pour leur vaccin de nouvelle génération contre le COVID-19.
L'événement offre aux actionnaires et aux investisseurs l'opportunité d'interagir avec M. Dodd en temps réel. Les participants peuvent soumettre des questions à l'avance ou pendant l'événement. L'inscription est requise pour assister et recevoir des mises à jour. Pour ceux qui ne peuvent pas se joindre en direct, un webcast archivé sera disponible sur EmergingGrowth.com et la chaîne YouTube de Emerging Growth.
GeoVax Labs, Inc. (Nasdaq: GOVX), ein Biotechnologieunternehmen, das Immuntherapien und Impfstoffe entwickelt, wird am 21. August 2024 auf der Emerging Growth Conference präsentieren. Der Vorsitzende und CEO David Dodd wird um 16:10 Uhr ET eine interaktive Live-Präsentation halten, in der er über die aktuellen Mpox Entwicklungen und wichtige Meilensteine im Zusammenhang mit dem BARDA Project NextGen Award für ihren Impfstoff der nächsten Generation gegen COVID-19 spricht.
Die Veranstaltung bietet Aktionären und Investoren die Möglichkeit, in Echtzeit mit Herrn Dodd zu interagieren. Die Teilnehmer können im Voraus oder während der Veranstaltung Fragen einreichen. Eine Registrierung ist erforderlich, um teilzunehmen und Updates zu erhalten. Für diejenigen, die nicht live dabei sein können, wird eine archivierte Aufzeichnung auf EmergingGrowth.com und dem Emerging Growth YouTube-Kanal verfügbar sein.
- None.
- None.
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the
BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chairman and CEO, David Dodd, in real time.
Mr. Dodd will be presenting at 4:10pm ET on Wednesday, August 21, 2024. Following his presentation, Mr. Dodd will open the floor for questions, time permitting. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions are conducted through video webcasts and take place in the Eastern time zone.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When is GeoVax (GOVX) presenting at the Emerging Growth Conference?
What topics will GeoVax (GOVX) discuss during the Emerging Growth Conference presentation?
How can investors participate in GeoVax's (GOVX) Emerging Growth Conference presentation?
Will there be a recording of GeoVax's (GOVX) Emerging Growth Conference presentation?
